Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer

by Vandana Singh, Benzinga Editor

July 27, 2021 2:03 PM | 1 min read |

The FDA has granted Orphan Drug Designation to Novartis AG's NVS NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer.
NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor cells and modulate the tumor microenvironment.
A Phase 2 study is ongoing, and a Phase 3 trial in the first-line metastatic pancreatic ductal carcinoma is planned to start enrolling patients later in 2021.
Price Action: NVS shares are up 0.27% at $91.21 during the market session on the last check Tuesday.
Related content: Benzinga's Full FDA Calendar.